Bell Investment Advisors’s Krystal Biotech KRYS Stock Holding History

Bell Investment Advisors’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.13K	Hold	16	–	–	﹤0.01%	1042
2025 Q4	$3.94K	Hold	16	–	–	﹤0.01%	1074
2025 Q3	$2.83K	Sell	16 -3	-16%	-$449	﹤0.01%	1192
2025 Q2	$2.61K	Hold	19	–	–	﹤0.01%	1261
2025 Q1	$3.43K	Sell	19 -9	-32%	-$1.51K	﹤0.01%	1088
2024 Q4	$4.39K	Buy	28 +9	+47%	+$1.6K	﹤0.01%	984
2024 Q3	$3.46K	Buy	19 +6	+46%	+$1.16K	﹤0.01%	1112
2024 Q2	$2.39K	Sell	13 -1	-7%	-$168	﹤0.01%	1279
2024 Q1	$2.49K	Buy	+14	New	+$1.95K	﹤0.01%	1252
2023 Q4	–	Sell	-4	Closed	-$464	–	1958
2023 Q3	$464	Buy	+4	New	+$488	﹤0.01%	1824
2021 Q4	$1K	Buy	+9	New	+$524	﹤0.01%	1492

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bell Investment Advisors's KRYS Position: Q1 2026 in Review

Bell Investment Advisors held its Krystal Biotech (KRYS) position steady in Q1 2026 at 16 shares worth $4.13K. The position accounts for ﹤0.01% of the portfolio, ranked #1042.

Bell Investment Advisors first reported a position in KRYS in Q4 2021 and has held it in 11 quarters since. The position peaked at $4.39K in Q4 2024. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

Bell Investment Advisors held 16 shares of Krystal Biotech worth $4.13K as of Q1 2026.
Bell Investment Advisors left its Krystal Biotech share count unchanged in Q1 2026.
Krystal Biotech made up ﹤0.01% of Bell Investment Advisors's portfolio in Q1 2026, its #1042 holding.
Bell Investment Advisors first reported a position in Krystal Biotech in Q4 2021 and has held it in 11 quarters since.
Bell Investment Advisors's Krystal Biotech position peaked at $4.39K in Q4 2024.
367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Bell Investment Advisors's 13F filing for Q1 2026, filed 17 Apr 2026.